



HHS Public Access

Author manuscript

Cancer Prev Res (Phila). Author manuscript; available in PMC 2022 July 11.

Published in final edited form as:

Cancer Prev Res (Phila). 2022 June 02; 15(6): 412. doi:10.1158/1940-6207.CAPR-22-0203.

Retraction: Carnosol, a Constituent of Zyflamend, Inhibits Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and Mutagenesis

Arash Mohebati,
Joseph B. Guttenplan,
Amit Kochhar,
Zhong-Lin Zhao,
Wieslawa Kosinska,
Kotha Subbaramaiah,
Andrew J. Dannenberg

This article (1) has been retracted at the request of the authors. There was evidence of data falsification or fabrication found in two panels of Fig. 4. Suspicious duplications of band images were found in Fig. 4A and Fig. 4B, and evidence is consistent with these bands being three sets of duplicates. A copy of this Retraction Notice was sent to the last known e-mail addresses for the 7 authors. Three authors (Z.-L. Zhao, K. Subbaramaiah, and A.J. Dannenberg) agreed to the retraction; 4 authors (A. Mohebati, J.B. Guttenplan, A. Kochhar, and W. Kosinska) did not respond. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

Reference

1. Mohebati A, Guttenplan JB, Kochhar A, Zhao ZL, Kosinska W, Subbaramaiah K, et al. Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. *Cancer Prev Res* 2012;5:593–602.